Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2025—HER2 in predictive biomarker testing, HPV-related cancer testing guidelines, and the art of applying polygenic risk scores will be some of what’s heard in USCAP 2025 sessions next month in Boston.
February 2025—Intracranial mesenchymal tumors (IMT) are extremely rare and account for only 0.3 percent of soft tissue tumors. Most frequently, mesenchymal tumors occur in subcutaneous tissue; they are rarely described in the central nervous system. In addition, these tumors typically occur in young adults,1 with a median patient age of 14 (range: four to 70).
February 2025—Some of the CAP accreditation program requirements in the 2024 microbiology and transfusion medicine checklists, in the edition released Dec. 26, have been revised to simplify, clarify, and conserve resources. In transfusion, one new requirement was added to define policy requirements for the use of low-titer group O whole blood.
February 2025—Digital pathology, artificial intelligence, and anatomic pathology computer systems—seven participants in a Dec. 10, 2024 online roundtable talked with CAP TODAY publisher Bob McGonnagle about their experiences, plans, and predictions. Large academic center practices and small pathology practices—they considered all perspectives. Here is what they told us.
January 2025—Pathology informatics leaders at the University of Michigan are moving in steps to a fully digital practice as they put in place an innovative workflow for primary diagnosis. Fresh off their August launch of the new workflow program within their remodeled histology lab, informatics directors in the pathology department say Michigan Medicine is the first in the U.S. to have radiology and pathology operating in the same shared picture archiving and communication system, or PACS, and to implement the well-established DICOM standard for pathology workflow.
January 2025—The point-of-care checklist in the 2024 accreditation checklist edition, released Dec. 26, now includes requirements on coagulation specimen collection and handling.
January 2025—A study published last year found variability in the variants tested for in the commercial lab DPYD genotyping assays available at the time of the study, underscoring “the importance of comprehensive DPYD genotyping to accurately identify patients with DPD deficiency,” the authors said. Compromised dihydropyrimidine dehydrogenase deficiency raises a cancer patient’s risk of fluorouracil toxicity.
January 2025—Whether grade group 1 prostate cancer should be renamed to “noncancer” was the center of debate on a CAP podcast last fall led by Gladell P. Paner, MD, in discussion with Ming Zhou, MD, PhD, and Rajal B. Shah, MD. Dr. Paner is professor of pathology and surgery, University of Chicago Pritzker School of Medicine, and director of the genitourinary pathology service and of the reproductive endocrinology and infertility laboratory, UChicago Medicine.
January 2025—A clinical laboratory team at Ohio State University Wexner Medical Center took on a point-of-care testing problem common to other hospitals: documentation of critical result notification. At OSU, the documentation rate for point-of-care glucose critical result notification wasn’t high enough, and the team set out to raise it. It’s not sufficient to notify the physician or other provider. “You then have to prove you’re doing this, with documentation that the notification did in fact exist,” said Heather Stieglitz, PhD, D(ABCC), OSU co-director of clinical chemistry and toxicology, in an ADLM point-of-care testing session last summer.
January 2025—Renal mass biopsy has become an indispensable pre-management diagnostic tool, especially as incidental renal masses are increasingly detected with modern imaging techniques. It offers the patient the opportunity to get a definitive diagnosis without necessitating nephrectomy, especially helpful for patients with advanced disease or those who are poor surgical candidates. This is crucial, as certain renal cell carcinoma (RCC) subtypes have significantly different prognostic outcomes and therapeutic implications, making it essential to subtype RCCs in addition to distinguishing between benign and malignant lesions. For instance, systemic treatment strategies diverge markedly between clear cell RCC and non-clear cell RCC subtypes, underscoring our role in guiding personalized therapy choices. This article synthesizes key findings and diagnostic challenges most encountered on renal mass biopsy, with a focus on clear cell RCC, clear cell papillary renal cell tumor, TFE3-rearranged RCC, papillary RCC, oncocytoma, and chromophobe RCC.
